RxDoctor Payments DataLook up a doctor →

Anil Om, MD

Interventional Cardiology · Florence, SCNPI 1972560332

Payments from drug & device makers

$20,877in general payments, 2019–2025

Across 489 payments — averaging $42.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$10K
  • Johnson & Johnson$2K
  • Novartis$982
  • Boston Scientific$536
  • Medtronic$524
  • E.r. Squibb & Sons, L.L.C.$518
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$6003%
  • Speaking & faculty fees$10,05048%
  • Travel & lodging$670%
  • Food & beverage$10,15949%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,877 in reported general payments places this provider in the 65th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$497,918
Medicare patients
4,146
Services billed
9,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban543$520,784
EntrestoSacubitril/Valsartan235$267,379
BrilintaTicagrelor193$119,594
XareltoRivaroxaban97$114,260
JardianceEmpagliflozin101$94,706
FarxigaDapagliflozin Propanediol85$83,608
Repatha SureclickEvolocumab40$46,675
Dofetilide102$13,669
Ranolazine ErRanolazine168$12,285
NexletolBempedoic Acid12$7,660
Metoprolol Succinate504$6,654
Atorvastatin Calcium439$4,261
SotalolSotalol Hcl121$3,319
ClopidogrelClopidogrel Bisulfate310$3,080
Losartan Potassium285$2,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$404$520,784543 claims
NovartisEntresto$982$267,379235 claims
AstraZenecaBrilinta, Farxiga$10,191$203,203278 claims
Johnson & JohnsonXarelto$2,369$114,26097 claims
Boehringer IngelheimJardiance$319$94,706101 claims
Esperion Therapeutics, Inc.Nexletol$279$7,66012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →